蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 1060|回复: 4
收起左侧

[行业动态] 印度配合<国家基本药品目录>计划制定新的<国家基本诊断目录>

[复制链接]
药士
发表于 2018-3-14 09:53:42 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
本帖最后由 beiwei5du 于 2018-3-14 09:55 编辑

印度配合<国家基本药品目录>计划成为首个制定新的<国家基本诊断目录>的国家


India to create new essential list to improve access to life-saving diagnostic tests

Pharmaceuticals-Healthcare/Biotech-Industry-The Economic Times / 2018-03-13 00:30

NEW DELHI: India has decided to chart out a new national list that could be used to improve access to reliable diagnostic tests in public healthcare facilities, according to the Indian Council of Medical Research. At a later stage, the list is expected to even bring down prices of these tests in the private sector, according to a senior government official close to the development.
“There was a discussion to create a list of essential diagnostics to regulate the cost and reliability of tests,” said the official on condition of anonymity.

The government is expected to form a working group to focus on creating an essential diagnostics list (EDL) by the end of the year, ICMR said in a release. The body held a national consultation along with the World Health Organisation and McGill University on Monday to debate the need for such a list, its potential benefits and challenges that would need to be addressed while drafting it, according to the release.

In the first phase, the list will focus on increasing access to essential diagnostics in primary health centres, one of the participants at the consultation on Monday told ET. The working group is expected to focus on high burden diseases like HIV, tuberculosis and malaria to create its list for these PHCs.

“This exercise brings the focus back on public healthcare delivery. Right now, there are PHCs that don’t even have a blood pressure monitor,” the official said.

For instance, only 39% of the PHCs in UP’s Fatehpur district perform malarial parasite testing by slide method, while none of its PHCs conduct tests for blood sugar, typhoid and dengue, according to a presentation made during the consultation on Monday.

“The National EML in India has been helpful in capping prices of a variety of products, and has increased access to important medicines. The same model could be used for diagnostics. Without diagnostics, good medicines can be wasted, misused or simply not used,” stated ICMR.

An essential list for diagnostics is expected to improve patient care, detection of outbreaks, increase affordability of tests and reduce out-of-pocket expenses for tests, according to the release. Participants at the consultation also expected the list to reduce abuse of antibiotics that have led to a growing issue of antimicrobial resistance in the country, it added.

It will also improve regulation and quality of diagnostic tests, strengthen accreditation and quality of diagnostic labs and inspire the research and development of new diagnostic tools, according to the discussion cited by ICMR.

“I am convinced that essential medicines require essential diagnostics, but diagnostics get little attention, funding and priority,” said Madhukar Pai, director of McGill Global Health Programs. India being the first country to develop a national EDL is a positive step, according to him. “WHO is also developing an EDL, but I think the impact will be seen only at the national level,” he said.

Inoreader.comInoreader.comInoreader.com




回复

使用道具 举报

药士
 楼主| 发表于 2018-3-14 10:01:04 | 显示全部楼层
我们的医保能支撑制定能广大造福百姓什么?
回复

使用道具 举报

药生
发表于 2018-3-14 11:25:18 | 显示全部楼层
现在受惠医保还少吗?
别的不说,现在农保热火朝天,尤其是老人基本做到的大病必保
回复

使用道具 举报

药徒
发表于 2018-3-14 14:42:09 | 显示全部楼层
印度医保?
回复

使用道具 举报

药师
发表于 2018-3-14 14:48:24 | 显示全部楼层
我怎么这么不喜欢印度呢
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  增值电信业务经营许可证编号:京B2-20243455  互联网药品信息服务资格证书编号:(京)-非经营性-2024-0033

GMT+8, 2025-9-10 20:06

Powered by Discuz! X3.4

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表